SEOUL – Samsung Bioepis Co. Ltd., an affiliate of Samsung Group, plans to supply its biosimilar Enbrel, SB4, from partner Biogen Inc.'s plant for the South Korean and European markets, and the aim is to mass produce the product as soon as it receives approvals, said a company official.
"It takes about 14 to 16 months to complete the regulatory process in Europe, so we expect to receive the approval in the first half of next year
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?